Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2485564 | 0.88 | MEN1 (0.45) | TP53ALDH1A1TSHRGLAMAP3K5 | |
| SCHEMBL12009980 | 0.87 | GRIN2D (0.43) | TP53GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1229239 | 0.87 | TP53 (0.41) | TP53ALDH1A1SMN1; SMN2TSHRGLA | |
| SCHEMBL39522 | 0.85 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL40302 | 0.84 | MEN1 (0.45) | TP53GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5785897 | 0.84 | MEN1 (0.44) | TP53GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5189407 | 0.84 | KDM5A (0.40) | TP53ALDH1A1SMN1; SMN2TSHRGLA | |
| SCHEMBL1830325 | 0.84 | MEN1 (0.44) | TP53GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1982721 | 0.82 | TP53 (0.46) | TP53ALDH1A1SMN1; SMN2TSHRGLA | |
| SCHEMBL7750180 | 0.80 | MEN1 (0.45) | TP53ALDH1A1SMN1; SMN2TSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114845718-B | Compounds for the treatment of ocular diseases associated with excessive angiogenesis | 活跃生物技术有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-12208091-B2 | Compounds for treatment of eye diseases associated with excessive vascularisation | ACTIVE BIOTECH AB (SE) | 2025-01-28 | — | — | US | disclosed |
| US-20230066364-A1 | Compounds for Treatment of Eye Diseases Associated With Excessive Vascularisation | ACTIVE BIOTECH AB (SE) | 2023-03-02 | — | — | US | disclosed |
| EP-4094765-A1 | COMPOUNDS FOR TREATMENT OF EYE DISEASES ASSOCIATED WITH EXCESSIVE VASCULARISATION | Active Biotech AB (SE) | 2022-11-30 | — | — | EP | disclosed |
| US-11478465-B2 | Compounds for treatment of eye diseases associated with excessive vascularisation | ACTIVE BIOTECH AB (SE) | 2022-10-25 | — | — | US | disclosed |
| CN-114845718-A | Compounds for the treatment of ocular diseases associated with excessive vascularization | 活跃生物技术有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-20210322400-A1 | Compounds for Treatment of Eye Diseases Associated With Excessive Vascularisation | ACTIVE BIOTECH AB (SE) | 2021-10-21 | — | — | US | disclosed |
| EP-3886858-A1 | COMPOUNDS FOR TREATMENT OF EYE DISEASES ASSOCIATED WITH EXCESSIVE VASCULARISATION | Active Biotech AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| WO-2021123142-A1 | COMPOUNDS FOR TREATMENT OF EYE DISEASES ASSOCIATED WITH EXCESSIVE VASCULARISATION | ACTIVE BIOTECH AB (SE) | 2021-06-24 | — | — | WO | disclosed |
| EP-2337779-B1 | 2-OXO-1,2-DIHYDRO-QUINOLINE MODULATORS OF IMMUNE FUNCTION | TEVA PHARMA (IL) | 2017-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230066364-A1 | Compounds for Treatment of Eye Diseases Associated With Excessive Vascularisation | CRYAB, ALDH1A2, VEGFA | TP53 3594/4885GRIN2D 4694/4885GRIN3B 3658/4885 |
| US-20210322400-A1 | Compounds for Treatment of Eye Diseases Associated With Excessive Vascularisation | CRYAB, ALDH1A2, VEGFA | TP53 3594/4885GRIN2D 4694/4885GRIN3B 3658/4885 |
| US-12208091-B2 | Compounds for treatment of eye diseases associated with excessive vascularisation | CRYAB, ALDH1A2, VEGFA | TP53 3594/4885GRIN2D 4694/4885GRIN3B 3658/4885 |
| US-11478465-B2 | Compounds for treatment of eye diseases associated with excessive vascularisation | CRYAB, ALDH1A2, VEGFA | TP53 3594/4885GRIN2D 4694/4885GRIN3B 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.